Explore the vast range of titles available.

Peyronnin, N.; Green, M.; Richards, C.P.; Owens, A.; Reed, D.; Chamberlain, J.; Groves, D.G.; Rhinehart, W.K., and Belhadjali, K., 2013. Louisiana's 2012 Coastal Master Plan: overview of a science-based and publicly informed decision-making process. Louisiana is in the midst of a land loss crisis that has claimed more than 4800 km2 since the 1930s. Unless aggressive, large-scale action is taken, Louisiana could lose an additional 4500 km2 in the next 50 years, resulting in a projected increase in annual damages from hurricane storm surge flooding of more than $23 billion. Louisiana's 2012 Coastal Master Plan is a long-term plan with clear economic, social, and environmental benefits, such as decreasing potential damages from storm surge by $5.3 billion to $18 billion. Implementation of projects in the master plan should result in no net loss of land after 20 years and an annual net gain of land after 30 years. To develop the plan, the Coastal Protection and Restoration Authority (CPRA) utilized a state-of-the-art systems approach to coastal planning and a science-based decision-making process that resulted in a funding- and resource-constrained plan that makes the greatest progress toward achieving a sustainable coast. A series of integrated, coastwide predictive models were developed to provide data for a new planning tool used to identify the suite of projects that would make the greatest progress toward meeting the master plan objectives while considering uncertainties in future environmental conditions. Recognizing that the success of the plan hinges on stakeholder support, as well as science, the CPRA also implemented a comprehensive outreach plan to obtain input and feedback from key stakeholders and the public. The resulting plan recommends a specific list of restoration and protection projects and has achieved widespread support.

Louisiana is in the midst of a land loss crisis that has claimed more than 4800 km2 since the 1930s. Unless aggressive, large-scale action is taken, Louisiana could lose an additional 4500 km2 in the next 50 years, resulting in a projected increase in annual damages from hurricane storm surge flooding of more than $23 billion. Louisiana's 2012 Coastal Master Plan is a long-term plan with clear economic, social, and environmental benefits, such as decreasing potential damages from storm surge by $5.3 billion to $18 billion. Implementation of projects in the master plan should result in no net loss of land after 20 years and an annual net gain of land after 30 years. To develop the plan, the Coastal Protection and Restoration Authority (CPRA) utilized a state-of-the-art systems approach to coastal planning and a science-based decision-making process that resulted in a funding- and resource-constrained plan that makes the greatest progress toward achieving a sustainable coast. A series of integrated, coastwide predictive models were developed to provide data for a new planning tool used to identify the suite of projects that would make the greatest progress toward meeting the master plan objectives while considering uncertainties in future environmental conditions. Recognizing that the success of the plan hinges on stakeholder support, as well as science, the CPRA also implemented a comprehensive outreach plan to obtain input and feedback from key stakeholders and the public. The resulting plan recommends a specific list of restoration and protection projects and has achieved widespread support. [PUBLICATION ABSTRACT]

BackgroundUrticaria following the COVID-19 vaccine was rarely reported and had a short self-limited resolution. However, there has been relatively little literature published on CSU induced by COVID-19 vaccines.PurposeWe describe a case series of patients who experienced CSU after SARS-CoV-2 vaccination.MethodsA retrospective case series of 10 patients referred to the Department of Clinical Pharmacology of the University of Monastir (January 2021–January 2022) and included for evaluation of urticaria after COVID-19 vaccination.ResultsThe median age was 31 years and patients were mostly female. Atopy was presented in 3 patients and urticaria was accompanied by angioedema in 6 patients. The median time interval between vaccination and the onset of urticaria was 28.5 h. The offended dose was the first one in 8 patients. The resolution of the eruption was observed at least 2 months later, despite the regular use of a full dose of antihistamine in nine patients. Polynuclear leucocytosis was identified in 5 patients. Anti-TPOAb was positive in one patient after receiving the BNT162b2 vaccine. Total serum IgE was elevated in 4 patients. Skin tests for the suspected vaccine as well as the vaccine excipient were negative.ConclusionWe add to the medical literature ten new cases of chronic spontaneous urticarial reactions following COVID-19 vaccines uncontrolled with high-dose first-generation H1 antihistamines.

A-10-year-old girl was referred to our department for multiple hyperpigmented plaques. One week previously, she had been given one suppository of acetylsalicylic acid - phenobarbital for fever. Twelve hours after the drug intake the child developed pruritic red plaques on the left thigh. Six weeks after resolution of the acute reaction, patch tests were performed separately, with phenobarbital and acetylsalicylic acid. On 48-hour reading, only the phenobarbital patch test on residual pigmented lesion was positive. Because of possible cross-reactions between aromatic anticonvulsants, subsequent patch tests using carbamazepine and phenytoin on residual pigmented lesions were performed. They were all negative at 48-hour reading. To our knowledge, only two isolated pediatric cases of Phenobarbital-induced FDE have been reported in the literature. In this case report, as it was difficult to determine whether phenobarbital or acetylsalicylic acid was responsible for this reaction, subsequent patch tests allowed the identification of the culprit component since it was positive to phenobarbital.

Case We describe a 55-year-old woman suffering from Sezary syndrome, had undergone chemotherapy consisting of cycles of cyclophosphamide and prednisone. 10 months later, she noticed a progressively increasing reticulated generalised pigmentation in the face, trunk and the extremities. Cylophosphamide was withdrawn. The hyperpigmentation began to clear slowly and gradually after 7 months. One year after cyclophosphamide withdrawal and facing the relapse of the disease, and its transformation to a large T cell lymphoma a mini CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) protocol was held, leading to a remarkable aggravation of the pigmentation. Conclusion This adverse drug reaction to cyclophosphamide is peculiar by its localization and distribution and should be known in order not to confuse with other dermatosis.